Peptide Synthesis: Delivering Cost Effective Strategies

Case study

As early as the 1920s, when isolated insulin was first used as a replacement therapy, peptides have been acknowledged as a valuable class of pharmaceutical compounds for their ability to promote natural therapeutic pathways. Despite their desirable profile combining high selectivity with low toxicity, technological advances in peptide synthesis have only recently caught up to provide manufacturing methods to meet demand. Now, CDMOs can draw upon multiple synthesis strategies to offer large-scale production of peptide APIs across a wide range of therapeutic applications.

In this case study, learn how our expert chemists design custom strategies to leverage the latest innovations in peptide synthesis for achieving high-quality, large-scale production at the lowest cost.